A balanced perspective of ACCORD Lipid - Philip Barter

Is there a role for fibrates in type 2 diabetes patients at LDL-C goal?

 Professor Philip Barter, HDL Forum Editor, Heart Research Institute, Sydney, Australia discusses the findings from ACCORD Lipid in the context of other fibrate studies.

 


More Detail...

High-density lipoprotein and inflammation - new insights

Atherosclerosis is a chronic inflammatory disease.The anti-inflammatory properties of HDL and their main apolipoprotein, apoA-I, is a topic that is currently attracting considerable interest, as discussed by Forum Editor Professor Kerry-Anne Rye, Heart Research Institute, Sydney, Australia.
More Detail...

Raising high-density lipoprotein cholesterol

HDL Forum spoke to Professor Philip Barter, Director of the Heart Research Institute, and Professor Kerry-Anne Rye, Head of the Lipid Research Group, Heart Research Institute, Sydney, Australia about new therapeutic developments for raising high-density lipoprotein (HDL) cholesterol, "good" cholesterol.
More Detail...

What do the torcetrapib imaging trials tell us?

HDL Forum Editor, Professor Philip Barter, Heart Research Institute, Sydney Australia discusses the implications of trials investigating the effects of torcetrapib on atherosclerosis progression.
More Detail...

Impaired high-density lipoprotein (HDL) in diabetic dyslipidaemia: new therapeutic horizons

Cardiovascular disease (CVD) is the most common cause of mortality, responsible for about one-third of all deaths globally, according to recent estimates from the World Health Organization.
More Detail...

Why we need new therapeutic strategies for raising high-density lipoprotein (HDL) cholesterol?

Epidemiological and observational studies have conclusively established low HDL-C as a strong, independent predictor of coronary heart disease (CHD). Conversely, subjects with high levels of HDL-C have a reduced CHD risk
More Detail...

How can we manage diabetic dyslipidaemia to reduce cardiovascular risk?

Dyslipidemia is one of the main risk factors responsible for the increased cardiovascular risk associated with type 2 diabetes. We clearly need to consider treatment effective against all components of this dyslipidaemia, to reduce this risk.

HDL Forum Editor Professor Philip Barter discusses the options available to clinicians for treating atherogenic diabetic dyslipidaemia. This commentary was based on a lecture on Diabetes and Cardiovascular risk on Dave.md
More Detail...